EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations

Anna Fochesato, Logan Brooks, Omid Bazgir, Philippe B Pierrillas, Candice Jamois, James Lu iD, Francois Mercier iD

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70113 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Anna Fochesato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational PKPD and Clinical Pharmacology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Machine Learning, Drug Development, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F. Hoffmann-La Roche Ltd, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Classic and hybrid pharmacometric‐machine learning models (hPMxML) are gaining momentum for applications in clinical drug development and precision medicine, especially within the oncology therapeutic area. However, standardized workflows are needed to ensure transparency, rigor, and effective communication for broader adoption. In this tutorial, we review pharmacometric (PMx) and machine learning (ML) reporting standards and evaluate them against hPMxML works in oncology contexts as a motivational example to identify current deficiencies and propose mitigation strategies for future efforts. The revealed gaps include insufficient benchmarking, absence of error propagation, feature stability assessments, and ablation studies, limited focus on external validation and final parametrization, and discrepancies between the performance metrics chosen and the original clinical questions. To address these, we propose a checklist for hPMxML model development and reporting, consisting of steps for estimand definition, data curation, covariate selection, hyperparameter tuning, convergence assessment, model explainability, diagnostics, uncertainty quantification, validation and verification with sensitivity analyses. This standardized approach is expected to enhance the reliability and reproducibility of hPMxML outputs, enabling their confident application in oncology clinical drug development, while fostering trust among all stakeholders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Machine LearningDrug DevelopmentAntineoplastic AgentsNeoplasmsHumansPrecision MedicineReproducibility of ResultsMedical Oncology

Stichwörter der Autor:innen

clinical drug developmentmachine learningpharmacometrics

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Translational PKPD and Clinical Pharmacology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Predictive Modeling, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Genentech Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.

ORCID-Profile: James Lu, Francois Mercier

Förderung

  • F. Hoffmann-La Roche Ltd
  • Roche

Zitieren

APA

Fochesato, A., Brooks, L., Bazgir, O., Pierrillas, P. B., Jamois, C., Lu, J., & Mercier, F. (2026). Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70113

Vancouver

Fochesato A, Brooks L, Bazgir O, Pierrillas PB, Jamois C, Lu J, et al. Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70113

BibTeX
@article{Fochesato2026,
  author = {Fochesato, Anna and Brooks, Logan and Bazgir, Omid and Pierrillas, Philippe B and Jamois, Candice and Lu, James and Mercier, Francois},
  title = {Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70113}
}
Kostenlos starten →